Withings unveiled the Body Scan 2 at CES 2026 in January, a home health station that looks like a bathroom scale but functions closer to a compact diagnostic lab, reading more than 90 biomarkers in a single standing session and using AI-driven analysis to flag early signs of hypertension, pre-diabetes and irregular heart rhythm. The device went on sale in the United States on July 15, 2026 for $599.95, positioning Withings squarely in the fast-growing market for at-home preventive health and longevity monitoring.
What a 90-Second Scan Actually Measures
Body Scan 2 combines 13-frequency bioimpedance spectroscopy, impedance cardiography and a 6-lead ECG in one unit. A quick Daily Scan, about 30 seconds, captures weight, body composition, heart rate and vascular age, while a longer Longevity Scan, roughly 90 seconds, adds a full ECG reading with atrial fibrillation detection, a Heart Age estimate, blood-oxygen saturation and a Nerve Response Score. The device also produces a Glucose Resilience score and a Vascular Age estimate derived from pulse wave velocity, alongside body-composition breakdowns across six zones of the body, including visceral fat. Eric Carreel, Withings’ chairman and co-founder, has said the device is meant to provide a comprehensive assessment of cardiovascular and metabolic health rather than the single weight number a traditional scale delivers.
Built With Cardiometabolic Researchers
Withings developed the device in collaboration with cardiometabolic research centers and says the underlying scoring models draw on that partnership, a claim that helped the product earn a CES Innovation Award. Every purchase includes a complimentary one-month trial of Withings+, the company’s subscription layer priced afterward at $9.95 a month or $99.50 a year, which unlocks advanced scores including Heart Age and Glucose Resilience along with an AI Health Assistant and personalized trend analysis over time.
From Smart Scales to a Clinical Business
The Body Scan 2 launch is not happening in isolation. Withings has spent the past decade building out a lineup of connected scales, blood pressure cuffs and sleep sensors aimed at consumers, and this year the company took a further step into formal healthcare by launching Withings Medical, a clinical care delivery branch that began serving the Medicare-eligible population on July 5, 2026 as a participant in the Centers for Medicare and Medicaid Services’ new ACCESS Model. That expansion signals Withings is trying to move beyond selling wellness gadgets toward becoming a reimbursed part of chronic-disease management.
The Case for Catching Problems Earlier
Proponents of home biomarker stations argue that hypertension and pre-diabetes routinely go undiagnosed for years because they produce no symptoms and patients only get checked during infrequent doctor visits. A device sitting in a bathroom that captures cardiovascular and metabolic trends daily, the argument goes, could surface a slow-building problem long before a once-a-year physical would. Withings has marketed Body Scan 2 explicitly around that gap, framing it as a longevity tool rather than a replacement for medical care.
The Skeptical Counterpoint
Cardiologists and endocrinologists have generally welcomed more frequent home monitoring but have also cautioned that bioimpedance and pulse-wave-derived scores are not equivalent to a clinical blood pressure cuff reading, a fasting glucose test or a diagnostic ECG read by a physician. Scores like Glucose Resilience or Vascular Age are proprietary composites rather than standardized clinical measures, meaning two different manufacturers’ devices could label the same person very differently. There is also a recurring concern in preventive-health circles that healthy, anxious users are the ones most likely to buy a $600 scale and obsess over daily fluctuations in scores that were never designed to be interpreted day to day. Because Withings, like most connected-device makers, does not publish the full underlying algorithms behind scores such as Glucose Resilience, outside researchers have limited ability to independently audit how reliably those numbers track an individual’s actual metabolic trajectory over months or years.
What Comes Next
With Withings Medical now operating inside a CMS reimbursement model, the company appears to be betting that regulatory and insurance validation, not just consumer marketing, will be what separates Body Scan 2 from the broader wave of AI-powered health gadgets. Whether cardiologists eventually treat its readings as genuinely actionable, or continue to regard them as a useful nudge toward a real doctor’s visit, will likely determine whether the device becomes a fixture of preventive care or another well-reviewed gadget gathering dust in a bathroom corner.
